Cytotoxic t cells and granzyme b associated with improved colorectal cancer survival in a prospective cohort of older women

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 4, 2017, Pages 622-631

  Prizment, Anna E ^a,b   Vierkant, Robert A ^c   Smyrk, Thomas C ^c   Tillmans, Lori S ^c   Nelson, Heather H ^a,b   Lynch, Charles F ^d   Pengo, Thomas ^e   Thibodeau, Stephen N ^c   Church, Timothy R ^a   Cerhan, James R ^c   Anderson, Kristin E ^a,b   Limburg, Paul J ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GRANZYME B; PARAFFIN; GRANZYME; GZMB PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CAUSE OF DEATH; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EMBEDDING; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; WOMEN'S HEALTH; COLORECTAL TUMOR; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GRANZYMES; HUMANS; LONGITUDINAL STUDIES; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES;

EID: 85017035709     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0641     Document Type: Article

References (49)

1. Surveillance, Epidemiology, and End Results (SEER) Program (www. seer. cancer. gov) Research Data (1973-2013), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 Submission. Available from: www. seer. cancer. gov.
2. Compton CC. Optimal pathologic staging: defining stage II disease. Clin Cancer Res 2007;13:6862s-70s.
3. Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med 2010;134:837-52.
4. Chaput N, Svrcek M, Auperin A, Locher C, Drusch F, Malka D, et al. Tumour-infiltrating CD68 and CD57 cells predict patient outcome in stage II-III colorectal cancer. Br J Cancer 2013;109:1013-22.
5. Mlecnik B, Bindea G, Pags F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011;30:5-12.
6. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113-30.
7. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diag 2008;10:13-27.
8. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
9. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF-and KRAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010;127:367-80.
10. Sinicrope FA,Okamoto K, Kasi PM, KawakamiH. Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol 2016;14:651-8.
11. Phipps A, Limburg P, Baron J, Burnett Hartman A, Weisenberger D, Laird P, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015;148:77,87. e2.
12. Deschoolmeester V, Baay M, Lardon F, Pauwels P, Peeters M. Immune cells in colorectal cancer: prognostic relevance and role of MSI. Cancer Microenviron 2011;4:377-92.
13. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
14. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
15. Galon J, Costes A, Sanchez Cabo F, Kirilovsky A,Mlecnik B, Lagorce-Pags C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
16. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
17. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
18. Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 2014;110:1595-605.
19. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol2010;222:350-66.
20. Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ. T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 1997;40:113-9.
21. Salama P, PhillipsM, Platell C, Iacopetta B. Low expression of granzyme B in colorectal cancer is associated with signs of early metastastic invasion. Histopathology 2011;59:207-15.
22. Guidoboni M, Gafa R, Viel A, Doglioni C, Russo A, Santini A, et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. AmJ Pathol 2001;159:297-304.
23. Deschoolmeester V, Baay M, VanMarck E, Weyler J, Vermeulen P, Lardon F, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010;11:1.
24. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8.
25. Ling A, Edin S, Wikberg ML, Oberg Å, Palmqvist R. The intratumoural subsite and relation of CD8 and FOXP3 T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer 2014;110:2551-9.
26. Baker K, Zlobec I, Tornillo L, Terracciano L, Jass JR, Lugli A. Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-b pathway. Eur J Cancer 2007;43:624-31.
27. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol 2008;61:561-9.
28. Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, et al. Correlation between density of CD8 T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res 2015;75:3446-55.
29. Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. the Iowa Women's Health Study. Cancer 1995;76:275-83.
30. Folsom AR, Kushi LH, Anderson KE, Mink PJ, Olson JE, Hong C, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: The Iowa Women's Health Study. Arch Intern Med 2000;160:2117-28.
31. Lee W, Park S, Lee WY, Yun SH, Chun H. Clinical impact of tumorinfiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010; 116:5188-99.
32. Schernhammer ES, Giovannucci E, Baba Y, Fuchs CS, Ogino S. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PLoS One 2011;6:e21102.
33. Sommer C, Straehle C, Kothe U, Hamprecht FA. Ilastik: Interactive learning and segmentation toolkit. 2011 IEEE International Symposium on Biomedical Imaging: From Nano to Macro. IEEE; 2011. p. 230-3. Available from: http://ieeexplore. ieee. org/document/5872394/
34. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676-82.
35. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 2010;102:1012-22.
36. Samadder NJ, Vierkant R, Tillmans L, Wang A, Weisenberger D, Laird P, et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology 2013;145:348.
37. Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR, et al. Multimarker phenotype predicts adverse survival in patients with lymph nodenegative colorectal cancer. Cancer 2008;112:495-502.
38. Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, et al. Intraepithelial CD8 T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 2004;91:1711-7.
39. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8 T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
40. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumorinfiltrating FOXP3 T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-92.
41. Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011;105:93-103.
42. Phillips S, Banerjea A, Feakins R, Li S, Bustin S, Dorudi S. Tumourinfiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004;91:469-75.
43. Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 2008;26:389-420.
44. Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005;128: 1796-804.
45. Zhu Q, Liu J, Xu H, Yang C, Zhang A, Cui Y, et al. Mechanism of counterattack of colorectal cancer cell by fas/fas ligand system. World J Gastroenterol 2005;11:6125.
46. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016;44:698-711.
47. Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol 2015;16:64.
48. Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest 2015;125: 739-51.
49. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.